OPEN Foundation

Day: 19 December 2012

Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors

Abstract

Background
Serotonin (5-HT) 1A and 2A receptors have been associated with dysfunctional emotional processing biases in mood disorders. These receptors further predominantly mediate the subjective and behavioral effects of psilocybin and might be important for its recently suggested antidepressive effects. However, the effect of psilocybin on emotional processing biases and the specific contribution of 5-HT2A receptors across different emotional domains is unknown.

Methods
In a randomized, double-blind study, 17 healthy human subjects received on 4 separate days placebo, psilocybin (215 g/kg), the preferential 5-HT2A antagonist ketanserin (50 mg), or psilocybin plus ketanserin. Mood states were assessed by self-report ratings, and behavioral and event-related potential measurements were used to quantify facial emotional recognition and goal-directed behavior toward emotional cues.

Results
Psilocybin enhanced positive mood and attenuated recognition of negative facial expression. Furthermore, psilocybin increased goal-directed behavior toward positive compared with negative cues, facilitated positive but inhibited negative sequential emotional effects, and valence-dependently attenuated the P300 component. Ketanserin alone had no effects but blocked the psilocybin-induced mood enhancement and decreased recognition of negative facial expression.

Conclusions
This study shows that psilocybin shifts the emotional bias across various psychological domains and that activation of 5-HT2A receptors is central in mood regulation and emotional face recognition in healthy subjects. These findings may not only have implications for the pathophysiology of dysfunctional emotional biases but may also provide a framework to delineate the mechanisms underlying psylocybin’s putative antidepressant effects.

Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. (2012). Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors. Biological Psychiatry, 72(11), 898-906. http://dx.doi.org/10.1016/j.biopsych.2012.04.005
Link to full text

Labyrint: Mindblowing Therapy?

Will we be using Magic Mushrooms to fight depression? Or get an LSD treatment to cure your smoking addiction? On December 19 2012 Dutch Labyrint TV screened an episode about groundbreaking research using psychedelics in psychiatric treatment. Interviews with the scientists were filmed at OPEN’s Interdisciplinary Conference on Psychedelic Research in 2012.

First broadcast on the 19th of December, 2012 (English subtitles)

Labyrint: Geestverruimende Therapie

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][iframe id=”https://www.youtube.com/embed/n7X_mBoY0ZI”]

Paddo’s gebruiken om depressieve klachten te bestrijden? Of LSD-therapie om van je rookverslaving af te komen? Op 19 december 2012 zond Labyrint TV een aflevering uit over grensverleggend onderzoek naar het gebruik van psychedelica in de behandelkamer van de psychiater. Gefilmd tijdens Stichting OPEN’s Interdisciplinary Conference on Psychedelic Research in 2012.

Voor het eerst uitgezonden op 19 december 2012.[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

30 April - Q&A with Rick Strassman

X